Bertin Technologies news
Breast cancer remains one of the most challenging diseases to treat, especially for aggressive forms such as triple-negative breast cancer. Researchers are working relentlessly to better understand tumor metabolism and to find new therapeutic strategies. Two recent studies highlight how critical glutamine metabolism is in breast cancer cells:
We are proud to introduce Myelotracker®, a peptide-based probe. This unique technology specifically targets lactoferrin, a major protein stored in neutrophil granules, making it possible to visualize and study these immune cells with unmatched precision.
Unlike many existing tools, Myelotracker does not activate neutrophils, preserving their natural physiologica
Neutrophils are the most abundant white blood cells in the human body and among the very first immune cells to be recruited during inflammation. Yet despite their central role, their study has long been constrained by the lack of reliable tools to monitor their activity in real time. This limitation has made it difficult to fully grasp their contribution to health and disease.
Recent scientific progress is
It will be distinguished by its main mirror, 39 metres in diameter and made up of 800 segments, which will be phased and controlled by the Phasing Diagnostic Station (PDS) instrument.
Bertin Winlight will supply all the transport optics for the PDS, which will feed the various optica diagnostics. This involves the custom manufacture of 59 high-precision lenses, once again demonstrating the expertise of our teams in complex optical systems.
The ELT will enable major advances in
Ghrelin, widely recognized as the hunger hormone, is now under the spotlight for its role in mental health. Recent studies suggest that this metabolic signal may influence mood, especially in individuals with major depressive disorder (MDD). This connection between ghrelin and emotional states reve